肠道微生物组的组成和功能特征与阿尔茨海默病病理学有关
Jea Woo Kang1, Lora A Khatib2,3, Margo B Heston1
1Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA Address: 600 Highland Ave, J5/1 Mezzanine, Madison, WI, USA 53792.
medRxiv : the preprint server for health sciences
|September 16, 2024
概括
阿尔茨海默病 (AD) 与肠道微生物组的变化有关. 这项研究发现了阿尔茨海默病患者和健康个体之间肠道微生物的差异,将这些微生物与阿尔茨海默病生物标志物联系起来.
科学领域:
- 微生物组研究的研究.
- 神经退行性疾病的神经退行性疾病
- 阿尔茨海默病的病理学阿尔茨海默病的病理学.
背景情况:
- 肠道微生物组在阿尔茨海默病 (AD) 中的作用越来越被认可,但尚未完全理解.
- 关于与AD病理学相关的特定微生物组成和功能的知识有限.
研究的目的:
- 研究阿尔茨海默病患者肠道微生物组的组成和功能.
- 为了确定肠道微生物特征与AD和相关病理的已确定的生物标志物之间的关联.
主要方法:
- 来自威斯康星州微生物组在阿尔茨海默氏症风险研究中的便样本的浅枪元基因组测序.
- 对差异丰度和回归的分析,以将肠道微生物组特征与脑脊液 (CSF) 生物标志物联系起来.
主要成果:
- 在阿尔茨海默病患者和认知不受损的个体之间观察到肠道微生物组合和功能的显著差异.
- 这些组成差异在独立的队列中得到了验证.
- 发现特定的肠道微生物特征与AD和相关病理的CSF生物标志物有显著的关联.
结论:
- 在阿尔茨海默氏症中,肠道微生物的改变是显而易见的.
- 肠道微生物组及其代谢途径显然与AD的病理过程有关.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
983
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
